UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
March 29, 2004
Date of Report (Date of earliest
event reported)
NEORX CORPORATION
(Exact Name of Registrant as Specified in Charter)
Washington |
| 0-16614 |
| 91-1261311 |
(State or Other Jurisdiction |
| (Commission File No.) |
| (IRS Employer |
300 Elliott Avenue West, Suite 500, Seattle, Washington 98119-4114
(Address of principal executive offices) (Zip Code)
(206) 281-7001
(Registrant’s telephone number, including area code)
Item 5. Other Events
On March 29, 2004, NeoRx Corporation announced that it had opened the phase III clinical trial of its lead cancer therapeutic, STR™ (Skeletal Targeted Radiotherapy), to patient enrollment. See press release attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 7. Financial Statements and Exhibits
(c) Exhibits
Exhibit |
| Description |
|
|
|
99.1 |
| Press release dated March 29, 2004, announcing opening of phase III clinical trial for STR™ (Skeletal Targeted Radiotherapy) |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NEORX CORPORATION | ||
|
|
| |
|
|
| |
Dated March 31, 2004 | By | /s/ MELINDA G. KILE |
|
|
| Melinda G. Kile | |
|
| Vice President, Finance | |
2
Exhibit No. |
| Description |
|
|
|
99.1 |
| Press release dated March 29, 2004, announcing opening of phase III clinical trial for STR™ (Skeletal Targeted Radiotherapy) |
3
